Aptus Pharma Ltd
Aptus Pharma Q4 FY26: Revenue ₹40.36 Cr, PAT ₹21.31 Cr
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Aptus Pharma Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. EBITDA for the quarter: ₹36.11 crore, up 53.60% year-on-year - Operating margin: 20.2%, increased from 14.8% year-on-year - Profit after tax (PAT): ₹21.31 crore, up 42.82% year-on-year - Margin outlook: The presentation states the company is targeting sustained operating margins around 20%-22% going forward.
From Aptus Pharma Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026.
- This represents a year-on-year revenue growth of 16% compared to ₹34.80 crore in Q4 FY2025.
- Sales volume grew by 14% year-on-year during the quarter.
- The presentation highlights improvement in both domestic and export markets contributing to volume growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Aptus Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aptus Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Continue your research
What Aptus Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
- Remus Pharmaceuticals Ltd (Q4 FY26)
Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key concall takeaways from Remus Pharmaceuticals Ltd's Q4 FY26…
Frequently Asked Questions
What were Aptus Pharma Ltd Q4 FY26 results?
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. EBITDA for the quarter: ₹36.11 crore, up 53.60% year-on-year - Operating margin: 20.2%, increased from 14.8% year-on-year - Profit after tax (PAT): ₹21.31 crore, up 42.82% year-on-year - Margin outlook: The presentation states the company is targeting sustained operating margins around 20%-22% going forward.
What is Aptus Pharma Ltd share price analysis?
Aptus Pharma Ltd currently shows a neutral. The stock trades at a P/E of 131.2 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aptus Pharma Ltd planning capital expenditure?
The investor presentation mentions the following regarding capex, capacity expansion, and new projects: - Capex Plan: - Aptus Pharma is investing in capacity enhancement and new facility development.
Keep Aptus Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.